Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 144

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 144
---
), the pace and outcome of regulatory developments, and the success of internal testing and validation. There is no guarantee that foundational LLMs will advance at the necessary pace, that regulatory approvals will be secured, or that our internal testing will yield the results required for commercialization. Failure to address any of these risks could delay or prevent the launch of AI Agents and negatively impact our business strategy and operations. Our future AI Agents, which will be designed to provide personalized health guidance based on genomic, microbiome, clinical, and lifestyle data, present inherent risks. As these AI Agents will interact directly with customers, there is a potential for errors or inaccuracies in recommendations due to software limitations, algorithmic biases, or integration issues. Such inaccuracies could lead to adverse health outcomes, customer dissatisfaction, or legal claims, affecting our reputation and operations. While we will implement rigorous validation processes, the dynamic nature of AI technologies means unforeseen issues could arise, leading to potential liabilities. 48 Our development and deployment of AI Agents would rely on third -partyinfrastructures, including LLMs and other AI technologies which are continuously evolving. While these technologies provide significant potential to increase the scalability and efficiency of personalized healthcare, and enhance our ability to provide personalized health management services, they introduce risks related to the accuracy, reliability, and security of AI -generatedrecommendations, including bias, errors in medical interpretation, and the risk of overreliance by us and the end consumers of our products on automated outputs. AI Agents may produce incorrect, incomplete, or inappropriate responses, potentially affecting customer health outcomes. These risks are inherent to current AI technologies and may persist or evolve as technology advances. Additionally, regulatory frameworks for AI in healthcare are still emerging, and future legal requirements could impact our operations, requiring modifications to our AI systems. To mitigate these risks, we plan to implement screening and due diligence processes when selecting third -partyinfrastructure providers, ensuring alignment with industry best practices and relevant healthcare regulations. We aim to regularly monitor and assess third -partytechnologies for performance, security, and compliance, as well as the AI industry landscape. Where necessary, adjustments or replacements to these infrastructures may occur to ensure the safety, accuracy, and reliability of our AI Agents. Furthermore, maintaining human oversight where appropriate is a priority, integrating medical professionals into the process when a human touch is required, to ensure our AI solutions continue to meet high standards of care and regulatory compliance. All outputs generated by AI Agents will remain subject to human oversight, especially where medical recommendations are involved. Licensed